U.S. market Closed. Opens in 2 days 4 hours 42 minutes

FUSN | Fusion Pharmaceuticals Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 21.55 - 21.55
52 Week Range 21.55 - 21.60
Beta -0.41
Implied Volatility 51.61%
IV Rank 2.22%
Day's Volume N/A
Average Volume 2,109,086
Shares Outstanding 85,060,000
Market Cap 1,833,043,000
Sector Healthcare
Industry Biotechnology
IPO Date 2020-06-26
Valuation
Profitability
Growth
Health
P/E Ratio -15.39
Forward P/E Ratio N/A
EPS -1.40
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 101
Country Canada
Website FUSN
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
FUSN's peers: RLMD, RPTX
*Chart delayed
Analyzing fundamentals for FUSN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see FUSN Fundamentals page.

Watching at FUSN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on FUSN Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙